M. Shimojima

Identification of inosine monophosphate dehydrogenase as a potential target for anti-monkeypox virus agents

This study identifies IMPDH as a potential target for anti-monkeypox virus agents by showing that compounds targeting this enzyme inhibit MPXV replication more effectively than existing treatments.

Potential anti-monkeypox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments

This study identifies atovaquone, mefloquine, and molnupiravir as potential anti-monkeypox virus drugs, with atovaquone showing enhanced efficacy when combined with tecovirimat.

Development of a reverse transcription polymerase chain reaction for the detection of severe fever with thrombocytopenia syndrome virus from suspected infected animals

This paper develops an RT-PCR assay to detect SFTSV in suspected animals, identifying 5 positive cases among 56 samples and demonstrating its sensitivity and specificity.

The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral replication-transcription complex in culture cells

This paper identifies ciclesonide as an inhaled corticosteroid that inhibits SARS-CoV-2 replication by targeting the viral replication-transcription complex in cultured cells.

A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndrome

This paper develops and tests recombinant vaccinia virus vaccines against SFTS, showing they induce protective immunity and are safe in mice.

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15

The paper identifies ciclesonide as a corticosteroid that inhibits coronavirus replication by targeting NSP15, with resistance emerging through an amino acid substitution.

Characterization of the untranslated region of lymphocytic choriomeningitis virus S segment

This study investigates the functional roles of untranslated regions (UTRs) in the LCMV S segment, revealing their involvement in viral replication, transcription, and virulence, with implications for vaccine development.

Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: dose-efficacy studies upon oral administration

This study shows that oral favipiravir at 120 or 200 mg/kg/day effectively treats SFTSV infection in IFNAR-/- mice when started within 4 days post-infection, preventing mortality.